MrMed Logo
Deliver to

Chennai, 600017

Available Brands

Did you find this information helpful?

Author Details
mrmed authentic

Want to know more?
Read Our Editorial Policy

Quick Summary

LENVATINIB

LENVATINIB

Molecule Overview

Lenvatinib is an oral targeted medicine that blocks several growth-signal receptors involved in tumour blood vessel formation and cancer cell growth. It belongs to a class of medicines called multi-kinase inhibitors, used across thyroid, kidney, liver, and endometrial cancers. It is a prescription-only medicine.

Medical Classification

  • Therapeutic Class: Anti-cancer (oncology) targeted therapy.

  • Pharmacological Class: Multi-receptor tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT).

  • Drug Family: Small-molecule antiangiogenic kinase inhibitors.

  • ATC Classification: L01EK01 (Lenvatinib).

Conditions Treated

Approved: Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC); advanced renal cell carcinoma (RCC), combined with pembrolizumab as first-line treatment or with everolimus after prior anti-angiogenic therapy; unresectable hepatocellular carcinoma (HCC) as first-line treatment; and advanced endometrial carcinoma, combined with pembrolizumab, in specific biomarker-defined patients after disease progression on prior therapy.

Commonly used for: Patients with these specific advanced cancer types, generally after disease has progressed or is no longer suitable for other primary treatments like radioactive iodine or surgery.

Off-label use (only under medical guidance): Being studied in other solid tumours in clinical trials; not routine outside its approved indications.

Available Strengths & Dosage Forms

  • Oral capsules: 4 mg and 10 mg (also available as pre-packaged daily-dose combinations for 8 mg, 12 mg, 14 mg, 18 mg, 20 mg, and 24 mg total daily doses).

How the Molecule Works

Lenvatinib blocks multiple receptors — including VEGFR (vascular endothelial growth factor receptor), FGFR, PDGFR, RET, and KIT — that tumours rely on to form new blood vessels (angiogenesis) and to send growth signals. By blocking these pathways, lenvatinib helps starve tumours of their blood supply and slows cancer cell proliferation.

Dosage & Administration

  • Standard dose (DTC): 24 mg orally once daily, continued until disease progression or unacceptable toxicity.

  • Condition-wise dose (HCC, monotherapy): Weight-based: 12 mg once daily for patients 60 kg or more, or 8 mg once daily for patients under 60 kg.

  • Condition-wise dose (RCC or endometrial carcinoma, combined with pembrolizumab or everolimus): Dosing varies by combination and indication (commonly 20 mg once daily with pembrolizumab for RCC/endometrial carcinoma, or 18 mg once daily with everolimus for RCC) — refer to the specific combination regimen and the partner drug's prescribing information.

  • Route: Oral, once daily, at approximately the same time each day, with or without food.

  • Missed dose: If a dose is missed and it's not remembered within 12 hours of the scheduled time, skip it and take the next dose at the regular scheduled time.

  • Overdose: May worsen known side effects such as high blood pressure or bleeding; requires urgent medical attention.

Side Effects

  • Common: High blood pressure, fatigue, diarrhoea, decreased appetite, weight loss, nausea, mouth sores (stomatitis), and hand-foot skin reactions.

  • Serious: Cardiac dysfunction (heart failure), arterial blood clot events (heart attack, stroke), liver failure, kidney failure or impairment, gastrointestinal perforation or fistula formation, QT interval prolongation, bleeding events (including rare fatal hemorrhages, particularly in anaplastic thyroid cancer), and impaired wound healing.

  • Emergency symptoms: Chest pain, sudden weakness or slurred speech, severe abdominal pain, yellowing of the skin/eyes, significant bleeding, or a marked drop in urine output.

  • Recovery advice: High blood pressure is very common and usually managed with blood-pressure medicines rather than stopping treatment; regular monitoring allows the many possible serious effects to be caught and managed early through dose adjustment or interruption.

Warnings & Precautions

  • Pregnancy: Can cause fetal harm; effective contraception is required during treatment and for a period after stopping.

  • Breastfeeding: Not recommended during treatment and for a period after the last dose.

  • Liver disease: Dose reduction needed in severe impairment (Child-Pugh C) for DTC dosing; used with caution and monitoring across indications.

  • Kidney disease: Dose reduction needed in severe impairment for DTC and RCC dosing; used with caution and monitoring.

  • Elderly: Used with routine monitoring; may have increased sensitivity to certain side effects.

  • Children: Not established for use in children; a medicine for adult cancer patients.

Drug Interactions

  • Strong CYP3A4 and P-glycoprotein inhibitors/inducers: can alter lenvatinib levels; used with caution and monitoring.

  • Other blood-pressure-lowering medicines: often needed alongside lenvatinib to manage the high blood pressure it commonly causes, rather than a concern to avoid.

  • Other QT-prolonging medicines: increases the risk of heart rhythm effects when combined.

  • Everolimus or pembrolizumab (specific combination regimens): used together at adjusted, protocol-specific doses as part of approved combination therapy, not a general interaction to avoid.

Monitoring Requirements

  • Blood pressure checks, particularly during the first two months and periodically thereafter.

  • Liver and kidney function tests periodically.

  • Thyroid function (TSH) monitoring, given the effect on thyroid hormone suppression in DTC patients.

  • ECG and electrolyte monitoring in patients at risk of QT prolongation; cardiac function assessment periodically.

Alternative Molecules

Sorafenib, Cabozantinib (other multi-kinase inhibitors used in overlapping indications); Sunitinib, Pazopanib (other antiangiogenic kinase inhibitors, mainly RCC).

Combination Therapies

Used as monotherapy for DTC and first-line HCC; combined with pembrolizumab for RCC and endometrial carcinoma, and combined with everolimus for RCC after prior anti-angiogenic therapy.

  • Thyroid Cancer Medicines

  • Kidney & Liver Cancer Medicines

  • Multi-Kinase Inhibitors

FAQs

Q1.

What is lenvatinib used for?

It's used to treat certain advanced thyroid, kidney, liver, and endometrial cancers, either alone or in combination with other targeted or immune therapies.

Q2.

Why does lenvatinib commonly cause high blood pressure?

Because its blood-vessel-blocking (antiangiogenic) mechanism affects normal blood vessel function too, high blood pressure is one of the most common effects and is usually managed with blood-pressure medicines.

Q3.

Is lenvatinib used alone or with other cancer medicines?

It depends on the cancer type — it's used alone for thyroid cancer and first-line liver cancer, but combined with pembrolizumab or everolimus for kidney and endometrial cancers.

Q4.

What serious risks does lenvatinib carry?

It carries risks of heart problems, blood clots, liver and kidney issues, bleeding, and gastrointestinal perforation, among others, which is why regular monitoring throughout treatment is important.

Q5.

How long is lenvatinib treatment continued?

Generally until the disease progresses or side effects become unacceptable, as decided by the treating oncologist.

Disclaimer

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your oncologist to know if this treatment is appropriate for your condition.

;

Why MrMed?

Directly from

Directly from
Manufacturers

Quick Air

Quick Air
Delivery

Genuine

Genuine
Medicines

Up-to 85%

Up-to 85%
Discount

Why MrMed?

  • Genuine Medicines — Sourced from licensed manufacturers and their authorised distributors, with quality checks at every step.

  • Cold Chain Delivery — Temperature-controlled shipping for medicines that need it, to 4,000+ towns and cities across India.

  • Hard-to-Find Medicines — If a medicine is not available in India, we help you source it and support the documentation and approvals required.

  • Up to 85% Savings — Speciality treatments at a fraction of MRP.

We Create a Way. For You.

Serving customers and shipping medicines only within India.

Living with a serious health condition comes with enough challenges. Finding the right medicine shouldn't be one of them.

MrMed helps patients and caregivers in India buy speciality medicines online for cancer, kidney disease, heart conditions, and other complex long-term illnesses. If a prescribed medicine isn't available in India, we also help source and import it from trusted global suppliers while managing the required documentation and approvals.

From genuine medicine sourcing and cold chain delivery to patient support services, we make it easier to access treatment with confidence. Every step is built around one goal: helping you get the medicines you need, when you need them.

Why Patients Trust MrMed

  • 7,000+ speciality medicines across multiple therapeutic areas like oncology, nephrology, cardiology, and critical care medicines

  • Delivery to 4,000+ towns and cities across India

  • Up to 85% savings on speciality medicines

  • Medicines sourced from licensed manufacturers and authorised suppliers

  • Secure ordering through the MrMed website and app

  • Dedicated support for patients and caregivers

MrMed by the Numbers

The trust placed in MrMed is reflected in the lives we've been able to support.

  • ₹125+ crores saved by our users

  • ₹75 saved every second on cancer medicine, heart conditions, and more

  • Helping patients access treatment across India

Beyond Medicine Delivery

We support patients throughout their treatment journey with services that go beyond medicine delivery.

  • Guidance on Patient Assistance Programs (PAPs)

  • Support for accessing prescribed imported medicines

  • Dedicated customer support before and after your order

  • Assistance in finding difficult-to-access speciality medicines

Recognised for Excellence

MrMed has been recognised by leading industry platforms for our work in improving access to speciality healthcare through trust, innovation, and responsible care.

  • Healthcare Start-up of the Year by the Federation of Indian Chambers of Commerce & Industry (FICCI)

  • ET Pharma Game Changer Award for our contribution to speciality healthcare access

  • Selected for the Google Play Accelerator India 2026 Cohort, joining 20 AI-first startups chosen by Google

  • BW Healthcare 40 Under 40 recognition received by our founders, Dev and Saurab, in different years

  • Recognised among Brands to Watch Out For by Local Samosa

Trusted Healthcare, Verified Standards

MrMed is LegitScript Certified, reflecting our commitment to trusted, transparent, and responsible healthcare services. This certification reinforces our focus on maintaining high standards in online healthcare practices and patient safety.

Start Your Treatment Journey with Confidence

Whether you're ordering a regular prescription or looking for a difficult-to-find speciality medicine, MrMed is here to help.

Explore our catalogue and order medicines online with confidence through the MrMed website or app.

Download the MrMed App For Super-Fast Delivery!

MrMed is India's largest online pharmacy for super speciality medicines, offering an extensive range of drugs that cater to diverse health needs across the country.

MrMed

Genuine medicines delivered all over India

MrMed

Sourced directly from reputable manufacturers

MrMed

Efficient storage for temperature-sensitive medicines

MrMedMrMed

Available on Google Play & App Store